Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma

被引：2
作者：
Khattak, Muhammad A. [1 ]
Bakr, Farrah [1 ]
Krzystanek, Marcin [2 ]
Szallasi, Zoltan [2 ,3 ]
Gerlinger, Marco [4 ]
Santos, Claudio [4 ]
Swanton, Charles [4 ]
Pickering, Lisa M. [1 ]
Gore, Martin E. [1 ]
Larkin, James M. G. [1 ]
机构：
[1] Royal Marsden Natl Hlth Serv Fdn Trust, London, England
[2] Tech Univ Denmark, DK-2800 Lyngby, Denmark
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Canc Res UK, London Res Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 07期
基金：
英国医学研究理事会;
关键词：
ENDOTHELIAL GROWTH-FACTOR; HYPERTENSION; INHIBITOR; CANCER; EVEROLIMUS; SORAFENIB; SURVIVAL; CYTOKINE; RISK;
D O I：
10.1200/JCO.2012.46.9353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：971 / 972
页数：3
相关论文
共 15 条
  • [1] Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
    Armstrong, Andrew J.
    George, Daniel J.
    Halabi, Susan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3402 - 3407
  • [2] Bhargava P, 2010, GEN CANC S SAN FRANC
  • [3] Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    Goodwin, R.
    Ding, K.
    Seymour, L.
    LeMaitre, A.
    Arnold, A.
    Shepherd, F. A.
    Dediu, M.
    Ciuleanu, T.
    Fenton, D.
    Zukin, M.
    Walde, D.
    Laberge, F.
    Vincent, M.
    Ellis, P. M.
    Laurie, S. A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (11) : 2220 - 2226
  • [4] Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
    Humphreys, Benjamin D.
    Atkins, Michael B.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (19) : 5947 - 5949
  • [5] mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
    Lane, Heidi A.
    Wood, Jeanette M.
    McSheehy, Paul M. J.
    Allegrini, Peter R.
    Boulay, Anne
    Brueggen, Joseph
    Littlewood-Evans, Amanda
    Maira, Sauveur-Michel
    Martiny-Baron, Georg
    Schnell, Christian R.
    Sini, Patrizia
    O'Reilly, Terence
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (05) : 1612 - 1622
  • [6] Motzer R, 2012, EUR SOC MED ONC C VI
  • [7] Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Grunwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Kay, Andrea
    Ravaud, Alain
    [J]. CANCER, 2010, 116 (18) : 4256 - 4265
  • [8] Negrier S, 2007, CANCER-AM CANCER SOC, V110, P2468, DOI 10.1002/cncr.23056
  • [9] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [10] Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
    Rini, Brian I.
    Cohen, Darrel P.
    Lu, Dongrui R.
    Chen, Isan
    Hariharan, Subramanian
    Gore, Martin E.
    Figlin, Robert A.
    Baum, Michael S.
    Motzer, Robert J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (09): : 763 - 773
12